[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
[2] Misra P, Singh S. Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective. Cancer Med. 2019;8(5):1976-95.
[3] Wang S, Mao W, Wang Y, Shi X, Wang W, Dai L, Zhang W. Surgical Compliance and Survival Outcomes for Patients with Stage T1-2 Non-Small-Cell Lung Cancer. Cancer Manag Res. 2020;12:3597-610.
[4] Liu R, Chen Z, Yi X, Huang F, Hu G, Liu D, Li X, Zhou H, Liu Z. 9za plays cytotoxic and proapoptotic roles and induces cytoprotective autophagy through the PDK1/Akt/mTOR axis in non-small-cell lung cancer. J Cell Physiol. 2019;234(11):20728-41.
[5] Yuan C, Tao X, Zheng D, Pan Y, Ye T, Hu H, Xiang J, Zhang Y, Chen H, Sun Y. The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer. J Surg Oncol. 2019;119(3):379-87.
[6] Rodrigues G, Choy H, Bradley J, et al (2015). Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol 5:149-55.
[7] Rodrigues G, Choy H, Bradley J, Rosenzweig KE, Bogart J, Curran WJ Jr, Gore E, Langer C, Louie AV, Lutz S, Machtay M, Puri V, Werner-Wasik M, Videtic GMM. Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. Pract Radiat Oncol. 2015;5(3):149-55.
[8] Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P; International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792-801.
[9] Fan L, Cao Q, Ding X, Gao D, Yang Q, Li B. Radiotranscriptomics signature-based predictive nomograms for radiotherapy response in patients with nonsmall cell lung cancer: Combination and association of CT features and serum miRNAs levels. Cancer Med. 2020;9(14):5065-74.
[10] Ma X, Cheng J, Zhao P, Li L, Tao K, Chen H. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management. J Cell Mol Med. 2020;24(13):7576-89.
[11] Wang J, Chu Y, Li J, Zeng F, Wu M, Wang T, Sun L, Chen Q, Wang P, Zhang X, Zeng F. Development of a prediction model with serum tumor markers to assess tumor metastasis in lung cancer. Cancer Med. 2020;9(15):5436-45.
[12] Overview of the SEER Program. Available online: https://seer.cancer.gov/about/ overview.html. (Accessed on 30 Aug 2019).
[13] Wu LL, Liu X, Jiang WM, Huang W, Lin P, Long H, Zhang LJ, Ma GW. Stratification of Patients With Stage IB NSCLC Based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual. Front Oncol. 2020;10:571.
[14] Wang X, Wang Z, Pan J, Lu ZY, Xu D, Zhang HJ, Wang SH, Huang DY, Chen XF. Patterns of Extrathoracic Metastases in Different Histological Types of Lung Cancer. Front Oncol. 2020;10:715.
[15] Li H, Wang Z, Yang F, Wang J. Development and validation of a nomogram for predicting cancer-specific survival of surgical resected stage I-II adenosquamous carcinoma of the lung. J Surg Oncol. 2020;121(6):1027-35.
[16] Arbour KC, Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. JAMA. 2019;322(8):764-74.
[17] Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998;352:257-63.
[18] Pang Z, Yang Y, Ding N, Huang C, Zhang T, Ni Y, Du J, Liu Q. Optimal managements of stage IIIA (N2) non-small cell lung cancer patients: a population-based survival analysis. J Thorac Dis. 2017;9(10):4046-56.
[19] Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006;24(19):2998-3006.
[20] Zhu X, Zhao M, Zhou L, Zhang M, Cao P, Tao L. Significance of examined lymph nodes number and metastatic lymph nodes ratio in overall survival and adjuvant treatment decision in resected laryngeal carcinoma. Cancer Med. 2020;9(9):3006-14.
[21] Sun M, Trinh QD. A Surveillance, Epidemiology and End Results (SEER) database malfunction: perceptions, pitfalls and verities. BJU Int. 2016 Apr;117(4):551-2.